The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient comprising: (i) determining the number of alleles of ApoE4 in the patient's genome; (ii) determining the combined expression level of at least three platelet proteins in a platelet sample from the patient; and (iii) comparing the resulting value of step (ii) to a control value, wherein the at least three platelet proteins include at least one isoform of alpha-tropomyosin containing exon 1a and at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 or mutant GSTO-1, wherein a result higher than the control value is indicative of Alzheimer's disease. The invention also provides a solid support comprising one or more ligands of at least one isoform of alpha-tropomyosin containing exon 1a, and one or more ligands of at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 protein and/or mutant GSTO-1 protein immobilized thereon.

A detection module and a method for operating the same are revealed. A nano-scale iridium oxide membrane is used as a detection film. After being in contact with different concentrations of hydrogen peroxide, the iridium oxide membrane is oxidized or reduced to generate iridium (III) ions (Ir.sup.3+) or iridium (IV) ions (Ir.sup.4+). Thus a voltage shift is generated. Whether hydrogen peroxide is contained in the sample can be checked by detection of changes in the voltage. A sample is formed by mixing serum and benzylamine. When the serum in the sample contains LOXL2 enzyme associated with breast cancer, the LOXL2 enzyme reacts with benzylamine to get hydrogen peroxide which is used as a detection medium.

The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.

Provided are methods for rating agave derived beverages, that include assigning each beverage a position on a scale of quality based on its content of MAO A inhibitors or MAO B inhibitors or both. Also provided are labels displaying the quality of an agave derived beverage that has been assessed using such methods.

A detection module and a method for operating the same are revealed. A nano-scale iridium oxide membrane is used as a detection film. After being in contact with different concentrations of hydrogen peroxide, the iridium oxide membrane is oxidized or reduced to generate iridium (III) ions (Ir.sup.3+) or iridium (IV) ions (Ir.sup.4+). Thus a voltage shift is generated. Whether hydrogen peroxide is contained in the sample can be checked by detection of changes in the voltage. A sample is formed by mixing serum and benzylamine. When the serum in the sample contains LOXL2 enzyme associated with breast cancer, the LOXL2 enzyme reacts with benzylamine to get hydrogen peroxide which is used as a detection medium.

A glutamate oxidase that requires no protease treatment is produced. A glutamate oxidase mutant having a deletion of a predetermined amino acid sequence is also disclosed.

An object of the present invention is to provide a convenient sampling method and kit for histamine measurement. The present invention provides a method and a kit which involve non-invasively sampling a specimen, and detecting histamine from the obtained sample.

The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.